| |||||||||||
| These Clone-1 TCR (also called Clone 1 Thy1.1 TCR or Cl.1 TCR) transgenic mice were designed to optimize conditions for tumor eradication by low avidity tumor-specific T cells and may also be useful in general studies of T cell avidity, tolerance, positive/negative selection, and activation. | |||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Type Coisogenic; Congenic; Major Histocompatibility Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Generation N8+N1F4pN1 Donating Investigator Linda Sherman, The Scripps Research Institute Description
Male mice that are hemizygous for the Clone-1 TCR (also called Clone 1 Thy1.1 TCR or Cl.1 TCR) transgene are viable, fertile, and normal in size. Females are very weak and have low fecundity. The donating investigator reports that all transgenic mice are prone to tumor development by 5-6 months of age. The transgene encodes a rearranged low avidity T cell receptor that recognizes an influenza virus hemagglutinin epitope (HA518-526) restricted by MHC class I H-2Kd. Flow cytometric analysis shows appropriate skewing towards the CD8+ T cell compartment in thymocytes and peripheral lymphocytes. Both naive and activated clone 1 T cells exhibit decreased responsiveness when presented with their cognate antigen in vitro and when transferred into mice expressing HA on pancreatic beta cells. CD8+ T cells can be induced to exhibit both effector function and antitumor activity. This mouse is further modified with the Thy1.1 allele, rather than the alternate allele present in C57BL/10, DBA/2, and BALB/c mice. Thus, cell populations derived from these transgenic mice can be distinguished from syngeneic host and other mice with the alternate allele via flow cytometry. These Clone-1 TCR (also called Clone 1 Thy1.1 TCR or Cl.1 TCR) transgenic mice were designed to optimize conditions for tumor eradication by low avidity tumor-specific T cells and may also be useful in general studies of T cell avidity, tolerance, positive/negative selection, and activation.Of note, Clone-1 TCR mice are also available on a BALB/cByJ congenic background (see Stock No. 005922).
Development
A low avidity influenza hemagglutinin (HA)-specific CD8+ T cell clone (Clone 1) was expanded from the tolerant repertoire of a transgenic mouse expressing HA as a self-antigen on insulin-producing beta cells of the pancreatic islets (InsHA mouse). This T cell receptor sequence, specific for influenza virus HA518-526 epitope restricted by MHC class I H-2Kd, was cloned into Tcra-V1,Tcra-J(J11) and Tcrb-V8.2,Tcrb-D,Tcrb-J(J2.4) expression vectors. The facility generating this mutant used "B10D2/nSnJ" mice derived from Stock No. 000463 as founder stock. The constructs were co-injected into fertilized B10D2/nSnJ eggs. Transgenic mice were bred to B10D2/nSnJ mice for 8 generations. Thereafter, transgenic mice were bred to B10D2/nSnJ mice homozygous for the Thy1a allele (coding for the Thy1.1 leukocyte alloantigen) to generate transgenic mice homozygous for Thy1a. Upon arrival at The Jackson Laboratory, transgenic Thy1a/a males were bred with Stock No. 000463 or wildtype sibling (Thy1.1 positive) females to generate Clone 1 transgene positive Thy1.1 positive mice.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying H2d allele
005308 B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 005534 B10.Cg-H2d Tg(Ins2-HA)165Bri/ShrmJ 000462 B10.D2-H2d/n2SnJ 000460 B10.D2-Hc0 H2d H2-T18c/o2SnJ 000461 B10.D2-Hc0 H2d H2-T18c/oSnJ 000463 B10.D2-Hc1 H2d H2-T18c/nSnJ 003147 B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J 000360 B6.C-H2d Mdmg1BALB/cBy/aByJ 000359 B6.C-H2d/bByJ 001893 BRVR.D2-H2d/J 000437 D1.C-H2d H2-T18c/SnJ 003153 WLC.C-H2d.GR-Mtv2/MorJ 003154 WLC.C-H2d/MorJ View Strains carrying H2d (13 strains)
001317 B6.Cg-Igha Thy1a Gpi1a/J 005023 B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J 000406 B6.PL-Thy1a/CyJ 000983 B6.PL/(84NS)CyJ 007687 BKa.Cg-Sox17tm1Sjm Ptprcb Thy1a/J 007686 BKa.Cg-Sox17tm2Sjm Ptprcb Thy1a/J 005307 CBy.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 005922 CBy.Cg-Thy1a Tg(TcraCl1,TcrbCl1)1Shrm/J 005443 CBy.PL(B6)-Thy1a/ScrJ 005686 NOD.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 004483 NOD.NON-Thy1a/1LtJ 002721 NOD.NON-Thy1a/J 005651 SJL.AK-Thy1a/TseJ 003961 SJL.Cg Thy1a-Noxo1hslt/J
005922 CBy.Cg-Thy1a Tg(TcraCl1,TcrbCl1)1Shrm/J
007901 B6.Cg-Tg(Thy1-Brainbow1.0)HLich/J 007911 B6.Cg-Tg(Thy1-Brainbow1.1)MLich/J 007921 B6.Cg-Tg(Thy1-Brainbow2.1)RLich/J 003710 B6.Cg-Tg(Thy1-CFP)23Jrs/J 007940 B6.Cg-Tg(Thy1-CFP/COX8A)C1Lich/J 007612 B6.Cg-Tg(Thy1-COP4/EYFP)18Gfng/J 007615 B6.Cg-Tg(Thy1-COP4/EYFP)9Gfng/J 005630 B6.Cg-Tg(Thy1-EYFP)15Jrs/J 003709 B6.Cg-Tg(Thy1-YFP)16Jrs/J 005627 B6.Cg-Tg(Thy1-YFP/Syp)10Jrs/J 003782 B6.Cg-Tg(Thy1-YFPH)2Jrs/J 007606 B6.Cg-Tg(Thy1-cre/ESR1,-EYFP)AGfng/J 006614 B6;CB-Tg(Thy1-CFP/COX8A)C1Lich/J 006617 B6;CB-Tg(Thy1-CFP/COX8A)S2Lich/J 007910 B6;CBA-Tg(Thy1-Brainbow1.0)LLich/J 008004 B6;SJL-Tg(Thy1-ECFP/VAMP2)1Sud/J 007610 B6;SJL-Tg(Thy1-cre/ESR1,-EYFP)VGfng/J 006554 B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/J 007880 B6SJL-Tg(Thy1-Stx1a/EYFP)1Sud/J 007856 B6SJL-Tg(Thy1-Syt1/ECFP)1Sud/J 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/J 008230 FVB(Cg)-Tg(Thy1-SOD1*G93A)T3Hgrd/J 006143 FVB/N-Tg(Thy1-cre)1Vln/J
Additional Web Information
Congenic Nomenclature
Phenotype
Phenotype Information
assigned by genotype
Tg(TcraCl1,TcrbCl1)1Shrm/0
B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm
- immune system phenotype
- abnormal T cell subpopulation ratio (MGI Ref ID J:97745)
- mice hemizygous for this transgene exhibit skewing of thymic and lymph node T cell populations toward the CD8+ compartment
- reproductive system phenotype
- abnormal fertility/fecundity (MGI Ref ID J:106230)
- pregnant hemizygous female mice usually die before giving birth
- tumorigenesis
- increased tumor incidence (MGI Ref ID J:106230)
- some, but not all, hemizygous transgenic mice develop tumors at 5-6 months of age
- hematopoietic system phenotype
- abnormal T cell subpopulation ratio (MGI Ref ID J:97745)
- mice hemizygous for this transgene exhibit skewing of thymic and lymph node T cell populations toward the CD8+ compartment
- behavior/neurological phenotype
- weakness (MGI Ref ID J:106230)
- female mice hemizygous for this transgene exhibit general physiological weakness
This mouse can be used to support research in many areas including:
Tcra relatedCancer Research
Tumor Resistance
Immunology and Inflammation Research
Rearranged Antigen-Specific T Cell Receptor Transgenes
Research Tools
Cancer Research (anti-tumor activity)
Immunology and Inflammation Research (T Cell Receptor Transgenics)
Tcrb relatedHematological Research
Immunological Defects
Immunology and Inflammation Research
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects
Research Tools
Cancer Research (specific T cell deficiency)
H2d relatedHematological Research
Immunological Defects
Immunology and Inflammation Research
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects
Thy1a relatedImmunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Research Tools
Genetics Research (Tissue/Cell Markers: T cell specific surface marker)
Immunology and Inflammation Research (T cell specific surface marker)
Genes & Alleles
Gene & Allele Information
| Allele Symbol | H2d | ||
|---|---|---|---|
| Allele Name | d variant | ||
| Allele Type | Spontaneous | ||
| Gene Symbol and Name | H2, histocompatibility-2, MHC | ||
| Chromosome | 17 | ||
| Gene Common Name(s) | H-2; MHC-II; | ||
| General Note | The d variant has been observed in the following strains: DBA/2, DBA/2J BALB/c, BALB/cByJ, BALB/cJ, C57BLKS, NZB | ||
| Allele Symbol | Tg(TcraCl1,TcrbCl1)1Shrm | ||
| Allele Name | transgene insertion 1, Linda Sherman | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | Clone-1 TCR; | ||
| Mutation Made By | Linda Sherman, The Scripps Research Institute | ||
| Strain of Origin | B10.D2-Hc1 H2d H2-T18c/nSnJ | ||
| Expressed Gene | Tcrb, T-cell receptor beta chain, mouse, laboratory | ||
| Expressed Gene | Tcra, T-cell receptor alpha chain, mouse, laboratory | ||
| General Note | CD8+ T cells bearing this transgene, when transferred to mice that develop pancreatic tumors expressing influenza virus HA, can be induced to exhibit both effector function and antitumor activity only if HA-responsive CD4+ T cells are co-transferred and the mice are subsequently infected with influenza virus. : J:97745 | ||
| Molecular Note | The transgene encodes a low avidity T cell receptor (TCR) that recognizes the influenza virus hemagglutinin (HA) epitope HA518-526 in the context of the H2-Kd MHC class I molecule. The rearranged Tcra and Tcrb genes, which have joined Valpha1/Jalpha11 and Vbeta8.2/D/Jbeta2.4, respectively, were amplified from cytotoxic T lymphocyte (CTL) clone 1. Clone 1 was derived from a transgenic B10.D2 mouse that expressed influenza virus HA as a self-antigen in pancreatic beta cells, which resulted in production of lower-avidity TCRs than those made by wild-type B10.D2 mice after infection with influenza virus strain A/PR/8/32. [MGI Ref ID J:97745] | ||
| Allele Symbol | Thy1a | ||
| Allele Name | a variant | ||
| Allele Type | Not Applicable | ||
| Common Name(s) | Thy-1.1; Thy1.1; Thy1a; | ||
| Gene Symbol and Name | Thy1, thymus cell antigen 1, theta | ||
| Chromosome | 9 | ||
| Gene Common Name(s) | CD7; CD90; FLJ33325; T25; Thy 1.2; Thy-1; Thy-1.2; Thy1.1; Thy1.2; | ||
| General Note |
The Thy1 locus determines an antigen present on cells of the thymus, a number of mouse leukemias, brain, and in lesser amounts on lymph node and spleen cells. The allele Thy1a determines an antigenic specificity, Thy-1.1, found in the AKR and RF strains; the allele Thy1b determines an antigenic specificity, Thy-1.2, found in the C3HeB/Fe and many other strains (J:5243, J:5012, J:4469). The Thy1 antigen is probably present on all T lymphocytes and absent from all B lymphocytes, and it thus serves as a valuable T-cell marker (J:5243). It is very widely used in experimentsdesigned to determine the distribution and function of T-cells. Thy1 specifies a T-cell surface glycoprotein, T25, with a molecular weight of 25 kDa (J:5707). The protein appears to be anchored in the cell membrane by a lipid that is either phosphotidylinositol or closely related to it (J:12016). Thy1 may function in the cell membrane as a signal transduction molecule (J:8333). The Thy1 locus, or possibly a gene closely linked to it, controls quantitative expression of a protein that is the same size as Thy1 and is expressed on thymus and brain but not on lymph node and spleen cells (J:7900). | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(TcraCl1,TcrbCl1)1Shrm, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
References
References
Selected Reference(s)
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA. 2005. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174(5):2563-72. [PubMed: 15728462] [MGI Ref ID J:97745]
Additional References
H2d relatedThy1a relatedAddis-Lieser E; Kohl J; Chiaramonte MG. 2005. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol 175(3):1894-902. [PubMed: 16034133] [MGI Ref ID J:107269]
Bakir HY; Tomiyama-Miyaji C; Watanabe H; Nagura T; Kawamura T; Sekikawa H; Abo T. 2006. Reasons why DBA/2 mice are resistant to malarial infection: expansion of CD3int B220+ gammadelta T cells with double-negative CD4- CD8- phenotype in the liver. Immunology 117(1):127-35. [PubMed: 16423048] [MGI Ref ID J:106141]
Bhadra S; Lozano MM; Payne SM; Dudley JP. 2006. Endogenous MMTV Proviruses Induce Susceptibility to Both Viral and Bacterial Pathogens. PLoS Pathog 2(12):e128. [PubMed: 17140288] [MGI Ref ID J:120299]
Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ. 1999. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 162(8):4373-6. [PubMed: 10201970] [MGI Ref ID J:119788]
Chiorazzi N; Fox DA; Katz DH. 1977. Hapten-specific IgE antibody responses in mice. VII. Conversion of IgE non-responder strains to IgE responders by elimination of suppressor T cell activity. J Immunol 118(1):48-54. [PubMed: 299762] [MGI Ref ID J:5739]
Clarke SR; Barnden M; Kurts C; Carbone FR; Miller JF; Heath WR. 2000. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 78(2):110-7. [PubMed: 10762410] [MGI Ref ID J:133645]
Croxford AL; Akilli-Ozturk O; Rieux-Laucat F; Forster I; Waisman A; Buch T. 2008. MHC-restricted T cell receptor signaling is required for alphabeta TCR replacement of the pre T cell receptor. Eur J Immunol 38(2):391-9. [PubMed: 18203137] [MGI Ref ID J:131357]
Dalloul AH; Ngo K; Fung-Leung WP. 1996. CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice. Eur J Immunol 26(1):213-8. [PubMed: 8566069] [MGI Ref ID J:112982]
El-Sawy T; Belperio JA; Strieter RM; Remick DG; Fairchild RL. 2005. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112(3):320-31. [PubMed: 15998678] [MGI Ref ID J:117219]
Fischer Lindahl K. 1997. On naming H2 haplotypes: functional significance of MHC class Ib alleles. Immunogenetics 46(1):53-62. [PubMed: 9148789] [MGI Ref ID J:41130]
Ford MS; Zhang ZX; Chen W; Zhang L. 2006. Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors. J Immunol 177(5):2803-9. [PubMed: 16920915] [MGI Ref ID J:139556]
Ghendler Y; Hussey RE; Witte T; Mizoguchi E; Clayton LK; Bhan AK; Koyasu S; Chang HC; Reinherz EL. 1997. Double-positive T cell receptor(high) thymocytes are resistant to peptide/major histocompatibility complex ligand-induced negative selection. Eur J Immunol 27(9):2279-89. [PubMed: 9341770] [MGI Ref ID J:133112]
Gubbels MR; Jorgensen TN; Metzger TE; Menze K; Steele H; Flannery SA; Rozzo SJ; Kotzin BL. 2005. Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice. J Immunol 175(9):6190-6. [PubMed: 16237116] [MGI Ref ID J:119371]
Klein J; Figueroa F; David CS. 1983. H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics 17(6):553-96. [PubMed: 6407984] [MGI Ref ID J:7097]
Krupnick AS; Gelman AE; Barchet W; Richardson S; Kreisel FH; Turka LA; Colonna M; Patterson GA; Kreisel D. 2005. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol 175(10):6265-70. [PubMed: 16272276] [MGI Ref ID J:119348]
Laky K; Lewis JM; Tigelaar RE; Puddington L. 2003. Distinct requirements for IL-7 in development of TCR gamma delta cells during fetal and adult life. J Immunol 170(8):4087-94. [PubMed: 12682238] [MGI Ref ID J:125438]
Legge KL; Braciale TJ. 2005. Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity 23(6):649-59. [PubMed: 16356862] [MGI Ref ID J:113311]
Mendiratta SK; Kovalik JP; Hong S; Singh N; Martin WD; Van Kaer L. 1999. Peptide dependency of alloreactive CD4+ T cell responses. Int Immunol 11(3):351-60. [PubMed: 10221647] [MGI Ref ID J:110542]
Miyashita N; Migita S; Moriwaki K. 1987. Effects of H-2 complex and non-H-2 background on urethane-induced chromosomal aberrations in mice. Mutat Res 176(1):59-67. [PubMed: 3099189] [MGI Ref ID J:109945]
Murphy DB. 1986. Overview: the murine MHC. In: Handbook of Experimental Immunology. Vol. 3, Genetic and Molecular Immunology. Blackwell Scientific Publ., Oxford. [MGI Ref ID J:30731]
Murphy WJ; Raziuddin A; Mason L; Kumar V; Bennett M; Longo DL. 1995. NK cell subsets in the regulation of murine hematopoiesis. I. 5E6+ NK cells promote hematopoietic growth in H-2d strain mice. J Immunol 155(6):2911-7. [PubMed: 7673708] [MGI Ref ID J:28582]
Oberg L; Johansson S; Michaelsson J; Tomasello E; Vivier E; Karre K; Hoglund P. 2004. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways. Eur J Immunol 34(6):1646-53. [PubMed: 15162434] [MGI Ref ID J:115484]
Porcellini S; Traggiai E; Schenk U; Ferrera D; Matteoli M; Lanzavecchia A; Michalak M; Grassi F. 2006. Regulation of peripheral T cell activation by calreticulin. J Exp Med 203(2):461-71. [PubMed: 16492806] [MGI Ref ID J:119147]
Poulin LF; Habran C; Stordeur P; Goldman M; McKenzie A; Van Snick J; Renauld JC; Braun MY. 2005. Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells. Eur Cytokine Netw 16(3):233-9. [PubMed: 16266865] [MGI Ref ID J:115764]
Reed-Loisel LM; Sullivan BA; Laur O; Jensen PE. 2005. An MHC class Ib-restricted TCR that cross-reacts with an MHC class Ia molecule. J Immunol 174(12):7746-52. [PubMed: 15944277] [MGI Ref ID J:109978]
Rodrigues OR; Moura RA; Gomes-Pereira S; Santos-Gomes GM. 2006. H-2 complex influences cytokine gene expression in Leishmania infantum-infected macrophages. Cell Immunol 243(2):118-26. [PubMed: 17316586] [MGI Ref ID J:120728]
Santiago ML; Montano M; Benitez R; Messer RJ; Yonemoto W; Chesebro B; Hasenkrug KJ; Greene WC. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321(5894):1343-6. [PubMed: 18772436] [MGI Ref ID J:138778]
Sho M; Yamada A; Najafian N; Salama AD; Harada H; Sandner SE; Sanchez-Fueyo A; Zheng XX; Strom TB; Sayegh MH. 2002. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol 169(7):3744-51. [PubMed: 12244168] [MGI Ref ID J:120408]
Sutton VR; Waterhouse NJ; Browne KA; Sedelies K; Ciccone A; Anthony D; Koskinen A; Mullbacher A; Trapani JA. 2007. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol 176(4):425-33. [PubMed: 17283185] [MGI Ref ID J:119725]
Ueno T; Habicht A; Clarkson MR; Albin MJ; Yamaura K; Boenisch O; Popoola J; Wang Y; Yagita H; Akiba H; Ansari MJ; Yang J; Turka LA; Rothstein DM; Padera RF; Najafian N; Sayegh MH. 2008. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 118(2):742-51. [PubMed: 18172549] [MGI Ref ID J:131045]
Varadhachary AS; Monestier M; Salgame P. 2001. Reciprocal induction of IL-10 and IL-12 from macrophages by low-density lipoprotein and its oxidized forms. Cell Immunol 213(1):45-51. [PubMed: 11747355] [MGI Ref ID J:115363]
Venkatesan P; Finch RG; Wakelin D. 1993. MHC haplotype influences primary Giardia muris infections in H-2 congenic strains of mice. Int J Parasitol 23(5):661-4. [PubMed: 8225770] [MGI Ref ID J:21687]
Wang L; Han R; Lee I; Hancock AS; Xiong G; Gunn MD; Hancock WW. 2005. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. J Immunol 175(10):6311-8. [PubMed: 16272282] [MGI Ref ID J:119345]
Zhang ZX; Yang L; Young KJ; DuTemple B; Zhang L. 2000. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6(7):782-9. [PubMed: 10888927] [MGI Ref ID J:118729]
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML. 2000. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 165(10):5580-7. [PubMed: 11067913] [MGI Ref ID J:119580]
Tg(TcraCl1,TcrbCl1)1Shrm relatedBeck PL; Li Y; Wong J; Chen CW; Keenan CM; Sharkey KA; McCafferty DM. 2007. Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology 132(5):1778-90. [PubMed: 17449036] [MGI Ref ID J:128325]
Chen TT; Li L; Chung DH; Allen CD; Torti SV; Torti FM; Cyster JG; Chen CY; Brodsky FM; Niemi EC; Nakamura MC; Seaman WE; Daws MR. 2005. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med 202(7):955-65. [PubMed: 16203866] [MGI Ref ID J:107466]
D'Eustachio P; Owens GC; Edelman GM; Cunningham BA. 1985. Chromosomal location of the gene encoding the neural cell adhesion molecule (N-CAM) in the mouse. Proc Natl Acad Sci U S A 82(22):7631-5. [PubMed: 3865183] [MGI Ref ID J:8111]
Fife BT; Griffin MD; Abbas AK; Locksley RM; Bluestone JA. 2006. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest 116(8):2252-61. [PubMed: 16886063] [MGI Ref ID J:113109]
Green MC; Sweet HO. 1975. [Hx - Hm - W.] Mouse News Lett 52:38. [MGI Ref ID J:13675]
Leiter EH. 1998. NOD Mice and Related Strains: Origins, Husbandry and Biology Introduction. In: NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancer, and Other Diseases. RG Landes, Austin. [MGI Ref ID J:110093]
Ranheim EA; Tarbell KV; Krogsgaard M; Mallet-Designe V; Teyton L; McDevitt HO; Weissman IL. 2004. Selection of aberrant class II restricted CD8+ T cells in NOD mice expressing a glutamic acid decarboxylase (GAD)65-specific T cell receptor transgene. Autoimmunity 37(8):555-67. [PubMed: 15763918] [MGI Ref ID J:128250]
Read S; Hogan TV; Zwar TD; Gleeson PA; Van Driel IR. 2007. Prevention of autoimmune gastritis in mice requires extra-thymic T-cell deletion and suppression by regulatory T cells. Gastroenterology 133(2):547-58. [PubMed: 17603058] [MGI Ref ID J:128303]
Voehringer D; Liang HE; Locksley RM. 2008. Homeostasis and effector function of lymphopenia-induced 'memory-like' T cells in constitutively T cell-depleted mice. J Immunol 180(7):4742-53. [PubMed: 18354198] [MGI Ref ID J:133382]
Wuthrich M; Warner T; Klein BS. 2005. IL-12 is required for induction but not maintenance of protective, memory responses to Blastomyces dermatitidis: implications for vaccine development in immune-deficient hosts. J Immunol 175(8):5288-97. [PubMed: 16210634] [MGI Ref ID J:119110]
Xiao Z; Mescher MF; Jameson SC. 2007. Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp Med 204(11):2667-77. [PubMed: 17954566] [MGI Ref ID J:126126]
Zaleski M; Klein J. 1974. Immune response of mice to Thy-1. 1 antigen: genetic control by alleles at the Ir-5 locus loosely linked to the H-2 complex. J Immunol 113(4):1170-7. [PubMed: 4606643] [MGI Ref ID J:5487]
Zaleski MB. 1975. Immune response of mice to the Thy-1.1 antigen: effect of the Ir-5 alleles studies in 129/J and B10.129(6M) mice Immunogenetics 2:241-8. [MGI Ref ID J:30773]
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ. 2008. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 68(8):2993-3000. [PubMed: 18413769] [MGI Ref ID J:133958]
Sherman L; Trenney RL. 2006. Overt phenotype of mice transgenic for CD8<sup>+</sup> Clone 1 T cell receptor Personal Communication :. [MGI Ref ID J:106230]
Health & husbandry
Health & Colony Maintenance Information
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, breed female Stock No. 000463 to trangenic positive/Thy1a positive males. Transgenic females are very poor breeders.
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00
Additional Supply Details
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
General Terms and Conditions
See Terms of Use
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.
For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice & Services Conditions of Use
“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
No Liability
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.